AstraZeneca PLC (LON:AZN) Stock Has Consensus Price Target of £150

Shares of AstraZeneca PLC (LON:AZN) have earned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is £150.

Several equities analysts have issued reports on AZN shares. Royal Bank Of Canada reissued an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £117 target price on shares of AstraZeneca in a research note on Tuesday, September 29th. Citigroup lifted their target price on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Jefferies Financial Group reiterated a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Wednesday, September 9th. Finally, Berenberg Bank cut their price target on shares of AstraZeneca from £160 to £150 and set a “buy” rating for the company in a report on Tuesday, September 15th.

AstraZeneca Price Performance

AstraZeneca stock opened at £119.58 on Friday. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. The business has a 50 day simple moving average of £120.93 and a 200-day simple moving average of £132.33. AstraZeneca has a 12 month low of £114.04 and a 12 month high of £157.32. The stock has a market capitalization of £185.46 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 0.86 and a beta of 0.20.

Insiders Place Their Bets

In other AstraZeneca news, insider Michel Demare acquired 2,500 shares of the stock in a transaction on Monday, September 14th. The shares were bought at an average price of £121.21 per share, with a total value of £303,025. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.